- Home
- ACON vs GOVX Comparison
ACON vs GOVX Comparison
Compare ACON & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACON | GOVX |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | 6 | 17 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 4.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACON | GOVX |
|---|---|---|
| Price | $3.22 | $1.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $23.00 | ★ $200.00 |
| AVG Volume (30 Days) | 69.3K | ★ 105.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $71.77 | N/A |
| Revenue Next Year | $80.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $0.12 |
| 52 Week High | $21.31 | $4.40 |
Technical Indicators
Market Signals| Indicator | ACON | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 45.26 |
| Support Level | $2.38 | $0.55 |
| Resistance Level | $7.84 | $4.40 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 73.27 | 48.00 |
Price Performance
Historical ComparisonAbout ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.